Scientist with rare ALS genetic mutation looks to experimental treatment

Jeff Vierstra, a scientist carrying a rare genetic mutation that predisposes him to ALS, has been receiving spinal infusions every few months for three years designed to target and disable the mutated gene before the disease develops. ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that typically causes paralysis and death within two to five years of diagnosis, making preventative genetic interventions potentially transformative for carriers of disease-causing mutations. Vierstra's case illustrates an emerging therapeutic approach: treating asymptomatic individuals who carry genetic risk factors before symptoms appear, rather than waiting until the disease has already caused irreversible nerve damage. The experimental treatment represents a significant shift in how researchers approach genetic diseases, offering hope to thousands of people worldwide who carry ALS mutations but have not yet developed symptoms. If successful, this model could provide a blueprint for early intervention in other genetic neurodegenerative conditions.